These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36849582)

  • 1. Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?
    Ewoldt TMJ; Bahmany S; Abdulla A; Muller AE; Endeman H; Koch BCP
    J Antimicrob Chemother; 2023 Apr; 78(4):1059-1065. PubMed ID: 36849582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid Chromatography-Tandem Mass Spectrometry to Monitor Unbound and Total Ceftriaxone in Serum of Critically Ill Patients.
    Meenks S; le Noble J; Foudraine N; de Vries F; Janssen P
    Curr Rev Clin Exp Pharmacol; 2021; 16(4):341-349. PubMed ID: 33371859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?
    Wong G; Briscoe S; Adnan S; McWhinney B; Ungerer J; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6165-70. PubMed ID: 24080664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.
    Ulldemolins M; Bastida C; Llauradó-Serra M; Csajka C; Rodríguez A; Badia JR; Martín-Loeches I; Soy D
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1169-1180. PubMed ID: 33559708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of unbound ceftriaxone in a critically ill population.
    Meenks SD; le Noble JLML; Foudraine NA; de Vries F; Neef K; Janssen PKC
    Int J Clin Pharmacol Ther; 2022 Sep; 60(9):373-383. PubMed ID: 35861497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis.
    Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2016 Dec; 48(6):748-752. PubMed ID: 27838278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia.
    Dreesen E; Gijsen M; Elkayal O; Annaert P; Debaveye Y; Wauters J; Karlsson MO; Spriet I
    J Antimicrob Chemother; 2022 Aug; 77(9):2479-2488. PubMed ID: 35815604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of total and unbound cefuroxime in plasma by ultra-performance liquid chromatography tandem mass spectrometry in a cohort of critically ill patients with hypoalbuminemia and renal failure.
    van Raaij JJ; Mabelis NJD; Shudofsky KN; Meenks SD; le Noble JLML; Janssen PKC
    J Clin Lab Anal; 2020 Mar; 34(3):e23100. PubMed ID: 31785116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study.
    Gijsen M; Dreesen E; Van Daele R; Annaert P; Debaveye Y; Wauters J; Spriet I
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34064676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board?
    De Cock PA; Desmet S; De Jaeger A; Biarent D; Dhont E; Herck I; Vens D; Colman S; Stove V; Commeyne S; Vande Walle J; De Paepe P
    J Antimicrob Chemother; 2017 Mar; 72(3):801-804. PubMed ID: 27999035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients.
    Sime FB; Byrne CJ; Parker S; Stuart J; Butler J; Starr T; Pandey S; Wallis SC; Lipman J; Roberts JA
    Crit Care; 2019 Jun; 23(1):205. PubMed ID: 31171022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients.
    Heffernan AJ; Sime FB; Kumta N; Wallis SC; McWhinney B; Ungerer J; Wong G; Joynt GM; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0218921. PubMed ID: 35575578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.
    Hartman SJF; Upadhyay PJ; Hagedoorn NN; Mathôt RAA; Moll HA; van der Flier M; Schreuder MF; Brüggemann RJ; Knibbe CA; de Wildt SN
    Clin Pharmacokinet; 2021 Oct; 60(10):1361-1372. PubMed ID: 34036552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.
    Schleibinger M; Steinbach CL; Töpper C; Kratzer A; Liebchen U; Kees F; Salzberger B; Kees MG
    Br J Clin Pharmacol; 2015 Sep; 80(3):525-33. PubMed ID: 25808018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients.
    Leegwater E; Kraaijenbrink BVC; Moes DJAR; Purmer IM; Wilms EB
    J Antimicrob Chemother; 2020 Jun; 75(6):1554-1558. PubMed ID: 32129853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High unbound flucloxacillin fraction in critically ill patients.
    Wallenburg E; Ter Heine R; de Lange DW; van Leeuwen H; Schouten JA; Ten Oever J; Kolwijck E; Burger DM; Pickkers P; Gieling EM; de Maat MM; Frenzel T; Brüggemann RJ
    J Antimicrob Chemother; 2021 Nov; 76(12):3220-3228. PubMed ID: 34463730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
    Ulldemolins M; Roberts JA; Rello J; Paterson DL; Lipman J
    Clin Pharmacokinet; 2011 Feb; 50(2):99-110. PubMed ID: 21142293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study.
    Bos JC; Prins JM; Mistício MC; Nunguiane G; Lang CN; Beirão JC; Mathôt RAA; van Hest RM
    J Antimicrob Chemother; 2018 Jun; 73(6):1620-1629. PubMed ID: 29522167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis.
    Brink AJ; Richards GA; Lautenbach EE; Rapeport N; Schillack V; van Niekerk L; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jun; 45(6):647-51. PubMed ID: 25819167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients-a population pharmacokinetic study.
    Tsai D; Zam BB; Tongs C; Chiong F; Sajiv C; Pawar B; Ashok A; Cooper BP; Tong SYC; Janson S; Wallis SC; Roberts JA; Parker SL
    J Antimicrob Chemother; 2023 Aug; 78(8):1963-1973. PubMed ID: 37367723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.